Investigation of effects of canola oil and soy bean oil in diabetes mellitus

Comparison of effects of canola oil and soybean oil on biochemical markers in overweight and obese patients with type 2 diabetes mellitus

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT2012062510110N1

Enrollment

Registered

2012-07-23

Start date

2012-07-15

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Condition 1: type 2 diabetes mellitus. Condition 2: Obesity. Non-insulin-dependent diabetes mellitus Obesity due to excess calories

Interventions

Intervention 1: Intervention 1 canola oil 30 grams daily for 2 months. Intervention 2: Intervention 2 soybean oil 30 grams daily for 2 months. Intervention 3: Control group Continue their previous die

Treatment - Other

Intervention 1 canola oil 30 grams daily for 2 months

Intervention 2 soybean oil 30 grams daily for 2 months

Control group Continue their previous diet for 2 months

Eligibility

Sex/Gender

All

Age

30 Years to 65 Years

Inclusion criteria

Inclusion criteria: Inclusion: Overweight or obese type 2 diabetes patients; 30 to 65 years old. Exclusion: Hyperglycemias not due to diabetes; liver, thyroid, kidney diseases; treatment with insulin; acute infections; anti lipid drugs; beta blockers; BMI= 24.9, BMI=40.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Blood Pressure. Timepoint: Beginning and 2 months after intervention. Method of measurement: Mercury sphigmomanometer.;Body Mass Index. Timepoint: Beginning and 2 months after intervention. Method of measurement: Measurment of Height and Weight and calculation by formula: Weight/Height2.;Fasting Glucose. Timepoint: Beginning and 2 months after intervention. Method of measurement: Available commercial kit.;HbA1c. Timepoint: Beginning and 2 months after intervention. Method of measurement: Available commercial kit.;Serum Lipids( TG,Chol, LDL, HDL, VLDL). Timepoint: Beginning and 2 months after intervention. Method of measurement: Available commercial kit.;Complete Blood Count (CBC). Timepoint: Beginning and 2 months after intervention. Method of measurement: Cell Counter.;Erythrocyte Sedimentation Rate (ESR). Timepoint: Beginning and 2 months after intervention. Method of measurement: ESR Pipette.;CRP. Timepoint: Beginning and 2 months after intervention. Method of measurement: Available commercial kit.	—

Measure

Time frame

Blood Pressure. Timepoint: Beginning and 2 months after intervention. Method of measurement: Mercury sphigmomanometer.;Body Mass Index. Timepoint: Beginning and 2 months after intervention. Method of measurement: Measurment of Height and Weight and calculation by formula: Weight/Height2.;Fasting Glucose. Timepoint: Beginning and 2 months after intervention. Method of measurement: Available commercial kit.;HbA1c. Timepoint: Beginning and 2 months after intervention. Method of measurement: Available commercial kit.;Serum Lipids( TG,Chol, LDL, HDL, VLDL). Timepoint: Beginning and 2 months after intervention. Method of measurement: Available commercial kit.;Complete Blood Count (CBC). Timepoint: Beginning and 2 months after intervention. Method of measurement: Cell Counter.;Erythrocyte Sedimentation Rate (ESR). Timepoint: Beginning and 2 months after intervention. Method of measurement: ESR Pipette.;CRP. Timepoint: Beginning and 2 months after intervention. Method of measurement: Available commercial kit.

—

Secondary

Measure	Time frame
Inflammatory and Antioxidant markers. Timepoint: Beginning and 2 months after intervention. Method of measurement: Available commercial kits.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr. Mansour Shahraki

Zahedan University of Medical Sciences

shahrakimansour@yahoo.com

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026